Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by longterm56on Oct 30, 2019 11:19pm

148 Views

Post# 30289892

RE:RE:Dr Colleen Hadigan emphasizes no more painful liver fat test

Forgive my cynicism, but it appears we are creating yet another list of "catalysts" ... yawn.

-LT

SPCEO1 wrote: I want to emphasize how important this attitude could be for TH's stock price. No analyst is currently incorporating the implications of this into their models. What if the US analysts not only give some actual credit for the long term possibilities for HIV NAFLD/NASH but also assume Egrifta patients rise from 8-900 now to 2,500 in a couple of years? That could happen. Say that translates into $0.80 per share in EPS? With a 15 P/E multiple on that we quickly get beyond the old high on that alone. And it is not far fetched to think that could happen.

Unomas69 wrote:
Another way of wording the below emphasis in yellow would go something like this I believe. - emphasizing there is no need to go threw a very painful testing from a doctor in a lab to see if your dealing with a fatty liver( heighten mortality) Since you have test for HIV and VAT(abdominal fat) I can just give you one medication and it will cover all three HIV, VAT and NAFLD( and in the future NASH ) So in simpler lamen terms Painful test or no test and one med... the best part is it could be the best justification for the FDA

I could be dreaming, what do y'all think WINO etc??

“Co-author Colleen Hadigan, MD, MPH, senior research physician at the National Institutes of Allergy and Infectious Diseases’ Laboratory of Immunoregulation, part of the NIH, agreed. “I think that this opens up an opportunity to rethink prescribing practices,” she told Contagion®, emphasizing that there’s no need for physicians to test for fatty liver in a patient who has HIV and abdominal fat before recommending tesamorelin. “This could be another piece of clinical information to justify adding another medication.””